VAC2VAC – Vaccine batch to vaccine batch comparison by consistency testing
After the VAC2VAC project was started in March 2016, the first annual meeting was held at the Paul-Ehrlich-Institut on 9 and on 10 March 2017. VAC2VAC is a consortium composed of both public and private members. It consists of 20 partners including pharmaceutical manufacturers of vaccines for human and veterinary use, academic institutes, and regulatory authorities.
Innovative medicines for Europe – Dr Martina Schüssler-Lenz of the Paul-Ehrlich-Institut elected chair of the EMA Committee for Advanced Therapies
In February this year, Dr Martina Schüssler-Lenz, clinical assessor at Division Medical Biotechnology of the Paul-Ehrlich-Institut (PEI) was elected chairperson of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA). Dr Schüssler-Lenz is a physician trained in internal medicine, and has specific expertise in the medical and regulatory field.
Inactivated rabies viruses carrying canine distemper glycoproteins protect against both pathogens
Currently licensed live attenuated canine distemper vaccines are highly effective. However, they retain the potential to cause disease in very susceptible species. Researchers at Paul-Ehrlich-Institut and Thomas Jefferson University have generated an inactivated candidate vaccine that induces protective immunity against both rabies and canine distemper and has an excellent safety profile.